<DOC>
	<DOCNO>NCT00101686</DOCNO>
	<brief_summary>This study compare first study period combination Irinotecan three different method administration Fluoropyrimidine . ( ie . infusion , bolus oral ) . In second period study compare FOLFIRI [ chemotherapy regime combine bolus irinotecan leucovorin [ LV ] infusional 5-fluorouracil ( 5-FU ) ] + bevacizumab mlFL + bevacizumab . Measures efficacy safety report .</brief_summary>
	<brief_title>Trial Of Irinotecan In Combination With Three Methods Of Administration Of Fluoropyrimidine .</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Diagnosis colorectal cancer ( either newly diagnose recurrent disease ) evidence metastatic disease . ( Stage IV distant disease ) Present past histological documentation adenocarcinoma colon rectum . The site primary lesion must confirm endoscopically , radiologically , surgically large bowel . Patients history colorectal cancer treat surgical resection develop radiological clinical evidence metastatic cancer require separate histological cytological confirmation metastatic disease unless : An interval great five year elapse primary surgery development metastatic disease . The primary cancer Duke 's A B1 . Physicians consider biopsy lesion establish diagnosis metastatic colorectal cancer case substantial clinical ambiguity regard nature source apparent metastasis . Patients receive prior systemic anticancer therapy metastatic colorectal cancer ( e.g. , chemotherapy , antibody therapy , immunotherapy , gene therapy , vaccine therapy , cytokine therapy , experimental agent ) . Patients concurrent malignancy study entry . Exceptions : Patients prior noncolorectal malignancy eligible diseasefree Â³ 3 year deem low risk recurrence treat physician ( e.g. , early stage prostate cancer , melanoma bladder cancer ) . Patients squamous basal cell carcinoma skin situ cervical cancer effectively treat eligible , even diagnose within 3 year randomization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
</DOC>